Guardant Complete
Backed by >80 clinical outcomes studies
and >350 peer-reviewed publications.
Explore some of the clinical data and discover how each test
provides insight for critical decisions across
the cancer continuum.
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients With Newly Diagnosed Metastatic Non-Small Cell Lung Cancer
Leighl NB, et al. Clin Cancer Res. 2019
Read more ›Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer
Page RD, et al. Clin Lung Cancer. 2022
Read more ›Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
Aggarwal C, et al. JAMA Oncol. 2019
Read more ›Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP)
Palmero R, et al. J Thorac Onc. 2018
Read more ›Up-Front Cell-Free DNA Next Generation Sequencing Improves Target Identification in UK First Line Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Cui W, et al. Eur J Cancer. 2022
Read more ›
Minimal Residual Disease Detection Using a Plasma-Only Circulating Tumor DNA Assay in Patients With Colorectal Cancer
Parikh AR, et al. Clin Cancer Res. 2021
Read more ›Multiomic, Plasma-Only Circulating Tumor DNA (ctDNA) Assay Identifies Breast Cancer Patients With Minimal Residual Disease (MRD) and Predicts Distant Recurrence (BRandO BiO Study)
Janni W, et al. AACR meeting. 2022
Read more ›
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients With Advanced Cancers Treated With Immune Checkpoint Blockade
Zhang Q, et al. Cancer Discov. 2020
Read more ›Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
Thompson JC, et al. JCO Precis Oncol. 2021
Read more ›